



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Panobinostat

Chemical Properties

CAS No. :	404950-80-7
Formula:	C ₂₁ H ₂₃ N ₃ O ₂
Molecular Weight:	349.43
Appearance:	no data available
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year



Biological Description

Description	Panobinostat (NVP-LBH589) is a broad-spectrum HDAC inhibitor (IC ₅₀ =5 nM) with oral activity and non-selectivity. Panobinostat has antitumor activity and induces apoptosis and autophagy.
Targets(IC ₅₀)	Apoptosis,HIV Protease,HDAC,Autophagy
In vitro	<p>METHODS: Thirty-seven lung cancer cell lines were treated with Panobinostat (0-800 nmol/L) for 48-72 h, and cell viability was measured using the MTT.</p> <p>RESULTS: Panobinostat showed potent antiproliferative activity and cytotoxicity against human and mouse lung cancer cell lines. [1]</p> <p>METHODS: Human ALL cells MOLT-4 and Reh were treated with Panobinostat (10-100 nM) for 24-72 h. Apoptosis was detected by Flow Cytometry.</p> <p>RESULTS: Panobinostat induced apoptosis in MOLT-4 and Reh cells in a time- and dose-dependent manner. [2]</p>
In vivo	<p>METHODS: To detect anti-tumor activity in vivo, Panobinostat (20 mg/kg) was intraperitoneally injected five times per week for two weeks into SCID mice bearing human SCLC tumors H526, BKT, RG1, or H69.</p> <p>RESULTS: Panobinostat significantly slowed down the in vivo growth of tumors derived from SCLC cells and induced remission. [1]</p> <p>METHODS: To investigate the potential for enhanced recovery of motor function after stroke, Panobinostat (3-10 mg/kg) was administered intraperitoneally to CD-1 mice with stroke every two days for ten days.</p> <p>RESULTS: Neither physical exercise nor the combination of Panobinostat substantially affected motor recovery in mice after stroke. Panobinostat treatment coupled with limited physical rehabilitation is unlikely to provide a therapeutic modality for stroke survivors with motor dysfunction. [3]</p>
Cell Research	Blasts from peripheral blood of 2 patients and from bone marrow of 4 patients were isolated with Ficoll-Hypaque, put in culture at a density of 500,000 cells/mL with RPMI-1640 medium containing 10% fetal bovine serum and 50 units/mL penicillin and streptomycin, and treated with different doses of LBH589 (0-100 μM) for up to 48 hours [1].
Animal Research	AE17 and TC-1 cancer cells (1 × 10 ⁶ cells) were injected into the flanks of adult female C57BL/6 mice and severe combined immunodeficiency (SCID) mice. M30 (10 × 10 ⁶ cells), A549 (5 × 10 ⁶ cells), H69 (2.5 × 10 ⁶ cells), BK-T (6.5 × 10 ⁶), H526 (10 × 10 ⁶), and RG1 (10 × 10 ⁶) cells were also injected, but in the presence of matrigel (BD

Biosciences), into the flanks of SCID mice. There were 5 to 10 mice in each treatment group. The experiments with the A549 and H69 cell lines were repeated to ensure the statistical consistency of the results. Experiments were terminated when the tumors in the control mice had grown to a size that threatened the quality of life of the mice. When tumors reached 100 to 500 mm³, panobinostat was administered via i.p. injections (10–20 mg/kg) on a daily schedule (5-days-on, 2-days-off regimen) for the entire duration of the experiment. Control mice received i.p. injections with dextrose 5% in water ("vehicle treatment"). Every tumor was measured with a caliper at least twice weekly. For evaluation of the effects of combination therapy on SCLC-derived tumors, SCID mice with H69 tumors were administered panobinostat as described above. Three days after the initiation of panobinostat, and again 1 wk later, etoposide (40 mg/kg) was administered i.p [3].

Solubility Information

Solubility	H ₂ O: < 1 mg/mL (insoluble or slightly soluble), Ethanol: < 1 mg/mL (insoluble or slightly soluble), DMSO: 16.67 mg/mL (47.7 mM), < 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.8618 mL	14.309 mL	28.618 mL
5 mM	0.5724 mL	2.8618 mL	5.7236 mL
10 mM	0.2862 mL	1.4309 mL	2.8618 mL
50 mM	0.0572 mL	0.2862 mL	0.5724 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Wellinger L C, Hogg S J, Newman D M, et al. BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity. *Cancer Immunology Research*. 2022, 10(1): 87-107.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481